Anat Globerson Levin

Author

Also Known As

A Globerson-Levin, A. Globerson Levin, Anat Globerson, Anat Globerson Levin, Anat Globerson-Levin, Anat Globerson-levin, Levin, Anat Globerson

Publications

463

Citations

H-Index

Concepts

All Affiliations

Tel Aviv University Weizmann Institute of Science Tel Aviv Sourasky Medical Center

About

Anat Globerson Levin is an author at Tel Aviv University specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	135
2	Cell Biology	4	4	87
3	Natural Sciences	1	1	48
4	Biochemistry	1	1	48
5	Chemical Biology	1	1	48

Anat Globerson Levin

Publications

367

Citations

H-Index

Page 1

	Year	Citations
Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response Raanan Greenman, Yoav Pizem, Maya Haus‐Cohen, Molecular Cancer Therapeutics	2021	56
Elimination of Progressive Mammary Cancer by Repeated Administrations of Chimeric Antigen Receptor-Modified T Cells Anat Globerson Levin, Tova Waks, Zelig Eshhar Molecular Therapy	2014	51
Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer Anat Aharon, Galit Horn, Tali Hana Bar-Lev, Human Gene Therapy	2021	51
Protein synthesis inhibitors and the chemical chaperone TMAO reverse endoplasmic reticulum perturbation induced by overexpression of the iodide transporter pendrin Jeanne Shepshelovich, Lee Goldstein-Magal, Anat Globerson Levin, Journal of Cell Science Molecular BiologyCytoskeletonChemical BiologyProtein FoldingEndocytic Pathway	2005	48
P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas Liat Rousso-Noori, Ignacio Mastandrea, Shauli Talmor, Nature Communications Dual AntitumorImmunologyImmunotherapeuticsHigh-grade GliomasImmunotherapy	2021	42
Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity Anat Globerson Levin, Moran Rawet Slobodkin, Tova Waks, Cancer Immunology Research	2020	33
T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields Gil Diamant, Hadar Simchony Goldman, Lital Gasri Plotnitsky, The Journal of Immunology	2021	27
Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer Eva Zupančič, Caterina Curato, Jung‐Seok Kim, Nanomedicine Nanotechnology Biology and Medicine NanomedicineCross-protectionTumor ImmunologyCancer ImmunosurveillanceImmunology	2018	19
Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells Yamit Shorer Arbel, Ben‐Zion Katz, Ronen Gabizon, Frontiers in Oncology	2021	14
Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach Anat Globerson Levin, Natalie Kronik, Tamar Shiloach, Cancer Immunology Immunotherapy ImmunologyImmunodominanceAntigen ProcessingAutoimmunityT Cell Immunity	2020	13

Page 1